Serine

Serine

SCHEMBL527447

N[C@@H](CO)C(=O)O.OB(O)O

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GGT1 P19440 4/20 0.52
SLC1A1 P43005 3/20 0.52
PTGS1 P23219 1/20 0.48
SLC7A11 Q9UPY5 1/20 0.48
ARG2 P78540 6/20 0.46
ARG1 P05089 4/20 0.46
GSR P00390 2/20 0.44
GRIK1 P39086 2/20 0.44
GRIK2 Q13002 2/20 0.44
GRM1 Q13255 2/20 0.44
GRM2 Q14416 2/20 0.44
SLC1A3 P43003 2/20 0.44
SLC1A2 P43004 2/20 0.44
SLC7A5 Q01650 1/20 0.44
GRM8 O00222 1/20 0.44
GRM6 O15303 1/20 0.44
GRIN2D O15399 1/20 0.44
GRIN3B O60391 1/20 0.44
CYP1A2 P05177 1/20 0.44
GRM5 P41594 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Serine SCHEMBL1681675 1.00 GGT1 (0.52) GGT1SLC1A1PTGS1SLC7A11ARG2
(D)-Serine SCHEMBL43094 0.91
Serine SCHEMBL6929773 0.91 SLC1A1 (0.59) GGT1SLC1A1PTGS1SLC7A11GSR
Serine SCHEMBL6520918 0.91 SLC1A1 (0.59) GGT1SLC1A1PTGS1SLC7A11GSR
(D)-Serine SCHEMBL6038168 0.91 SLC1A1 (0.59) GGT1SLC1A1PTGS1SLC7A11GSR
Serine SCHEMBL4455818 0.91 SLC1A1 (0.59) GGT1SLC1A1PTGS1SLC7A11GSR
Serine SCHEMBL6520912 0.91 SLC1A1 (0.59) GGT1SLC1A1PTGS1SLC7A11GSR
Serine SCHEMBL1332181 0.91
(D)-Serine SCHEMBL6660617 0.91 SLC1A1 (0.59) GGT1SLC1A1PTGS1SLC7A11GSR
Serine SCHEMBL6929758 0.91 SLC1A1 (0.59) GGT1SLC1A1PTGS1SLC7A11GSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8715646-B2 Methods of determining need for anti-coagulation therapy THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2014-05-06 US disclosed
US-20130209435-A1 METHODS FOR PREDICTING RISK OF STROKE THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2013-08-15 US disclosed
EP-2598881-A2 METHODS FOR PREDICTING RISK OF STROKE The Board of Trustees of the University of Illinois (US) 2013-06-05 EP disclosed
WO-2012016150-A2 METHODS FOR PREDICTING RISK OF STROKE THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2012-02-02 WO disclosed
US-5332755-A Leukotriene antagonists as antiinflammatory agents and antiallergens BAYER AKTIENGESELLSCHAFT (DE) 1994-07-26 US disclosed
US-5221760-A Intermediates, leukotriene antagonists BAYER AKTIENGESELLSCHAFT (DE) 1993-06-22 US disclosed
US-5159097-A An arylphosphorous compound as chemical intermediate BAYER AKTIENGESELLSCHAFT (DE) 1992-10-27 US disclosed
US-5118700-A Leukotriene antagonist BAYER AKTIENGESELLSCHAFT (DE) 1992-06-02 US disclosed
EP-0341551-B1 ALKENOIC ACID DERIVATIVES BAYER AG (DE) 1992-04-01 EP disclosed
US-5041638-A Leucotriene antagonist; treatment of respiratory system disorders, cardiovascular disorders BAYER AKTIENGESELLSCHAFT (DE) 1991-08-20 US disclosed
EP-0341551-A1 Alkenoic acid derivatives BAYER AG (DE) 1989-11-15 EP disclosed